What are the recommended topical and injectable anesthetic agents, dosing schedules, and safety limits for ocular procedures, and how should anesthesia be adjusted in patients allergic to amide local anesthetics?

Eye Anesthetics: Recommended Agents, Dosing, and Safety Limits

For ocular procedures, topical anesthetics (tetracaine, proparacaine) are first-line for minor procedures, while injectable amide anesthetics (lidocaine, bupivacaine) are used for more complex surgery, with maximum doses of 7 mg/kg lidocaine with epinephrine or 3 mg/kg bupivacaine with epinephrine; in patients with confirmed amide allergy, switch to ester-type anesthetics (procaine, chloroprocaine) as cross-reactivity between amide and ester classes is extremely rare.

Topical Anesthesia for Ocular Procedures

Topical anesthesia is appropriate for:

• Minor anterior segment procedures
• Unilateral surgery in adults
• Procedures requiring patient cooperation and eye movement 1

Common topical agents include:

• Tetracaine (ester): Maximum 1.5 mg/kg with epinephrine, 1 mg/kg without; duration 180-600 minutes 2, 3
• Proparacaine (ester): Widely used for brief procedures

Critical safety consideration: Topical anesthetics have significant abuse potential and direct corneal toxicity. Never dispense for home use. Abuse causes superficial punctate keratitis, persistent epithelial defects, stromal infiltrates, corneal edema, and endothelial damage—often misdiagnosed as acanthamoeba keratitis 4. The preservatives in these agents contribute substantially to toxicity.

Injectable Anesthesia: Amide Agents (First-Line)

For retrobulbar, peribulbar, or infiltrative anesthesia, amide local anesthetics are preferred due to lower allergenic potential compared to esters 5, 1.

Recommended Amide Agents and Maximum Doses

Agent	Max Dose WITH Epinephrine	Max Dose WITHOUT Epinephrine	Duration
Lidocaine	7.0 mg/kg	4.4 mg/kg	90-200 min
Bupivacaine	3.0 mg/kg	1.3 mg/kg	180-600 min
Ropivacaine	3.0 mg/kg	2.0 mg/kg	180-600 min
Mepivacaine	7.0 mg/kg	4.4 mg/kg	120-240 min

2, 3, 2

Dosing Calculations

Concentration conversion (essential for accurate dosing):

• 1% solution = 10 mg/mL
• 2% solution = 20 mg/mL
• 0.5% solution = 5 mg/mL
• 0.25% solution = 2.5 mg/mL 2, 3

Example: For a 70 kg patient using lidocaine with epinephrine:

• Maximum dose = 7 mg/kg × 70 kg = 490 mg
• Using 1% lidocaine (10 mg/mL) = 49 mL maximum
• Using 2% lidocaine (20 mg/mL) = 24.5 mL maximum

Critical Safety Measures to Prevent Systemic Toxicity

1. Calculate maximum allowable dose BEFORE administration based on patient weight 2, 3
2. Aspirate frequently before each injection to avoid intravascular injection 3
3. Use incremental injections rather than bolus dosing 6
4. Lower doses in highly vascular areas (conjunctiva, eyelids) 2, 3
5. Monitor vital signs every 5 minutes when using high doses or long-acting agents 3

Special Populations Requiring Dose Reduction

• Infants <6 months: Reduce amide doses by 30% due to immature hepatic metabolism 2, 3
• Elderly patients: Consider dose reduction due to altered pharmacokinetics 7
• Hepatic impairment: Articaine preferred (rapid plasma metabolism); reduce lidocaine/bupivacaine doses 7
• Renal impairment: Articaine preferred; caution with repeated dosing of other amides 7
• Cardiac disease: Mepivacaine preferred (minimal vasodilation); avoid exceeding 7 mg/kg toxic threshold 8, 7

Management of Amide Local Anesthetic Allergy

True immunologic allergy to amide local anesthetics is extremely rare (representing only 1% of all adverse reactions) 9, 10, 11. Most "allergic" reactions are actually:

• Vasovagal responses
• Anxiety reactions
• Toxic reactions from excessive dosing
• Reactions to preservatives (methylparaben) or epinephrine

When Amide Allergy is Confirmed

Switch to ester-type local anesthetics 6, 9:

Ester Agent	Max Dose WITH Epinephrine	Max Dose WITHOUT Epinephrine	Duration
Procaine	10.0 mg/kg	6.0 mg/kg	60-90 min
Chloroprocaine	20.0 mg/kg	12.0 mg/kg	30-60 min
Tetracaine	1.5 mg/kg	1.0 mg/kg	180-600 min

2, 3, 7

Rationale: Cross-reactivity between amide and ester classes is extremely rare because they have different metabolic pathways 9, 11. Esters are metabolized to para-aminobenzoic acid (PABA), while amides undergo hepatic metabolism. However, preservatives (methylparaben) in amide preparations are metabolized to PABA, which can cause confusion 11.

Alternative Strategies if Both Classes Contraindicated

If the rare patient has documented allergy to both amide AND ester anesthetics:

1. Preservative-free amide anesthetic (reactions often due to methylparaben, not the anesthetic itself) 11
2. 1% diphenhydramine infiltration (50 mg maximum) for minor procedures 6, 11
3. Bacteriostatic normal saline for brief procedures 6
4. General anesthesia for complex or bilateral procedures 5, 1

Diagnostic Approach Before Labeling "Anesthetic Allergy"

Do not empirically avoid all local anesthetics based on patient history alone. Most reported "allergies" are not immunologic 10, 11.

Refer for formal allergy testing when:

• History suggests possible true allergy (urticaria, angioedema, anaphylaxis)
• Future local anesthesia will be necessary
• Patient labeled "allergic to all caines"

Testing protocol includes 10, 11:

• Prick testing
• Intradermal testing with multiple agents
• Challenge testing with negative agents
• Testing of preservatives (methylparaben, metabisulfite)

Cross-reactivity patterns: Lidocaine-mepivacaine cross-reactivity occurs in documented allergic patients; test multiple agents from both classes 10.

Recognition and Management of Local Anesthetic Systemic Toxicity (LAST)

Early Warning Signs (Plasma Level 5-10 μg/mL)

• Circumoral tingling/numbness
• Metallic taste
• Tinnitus
• Lightheadedness
• Slurred speech 8

Severe Toxicity (Plasma Level >10 μg/mL)

• Muscle twitching
• Seizures
• Loss of consciousness
• Respiratory arrest
• Cardiac arrhythmias
• Ventricular arrest 8

Emergency Management Protocol

Immediate actions:

1. Stop injection immediately and call for help 2
2. Ventilate with 100% oxygen; secure airway if needed 2
3. Alert nearest facility with cardiopulmonary bypass capability 2
4. Manage seizures: IV midazolam 0.1-0.2 mg/kg (avoid propofol if cardiovascular instability) 2

Lipid emulsion rescue therapy (for cardiovascular collapse):

1. Administer 1.5 mL/kg of 20% lipid emulsion IV over ~1 minute 2
2. Start 20% lipid infusion at 0.25 mL/kg/min until circulation restored 2
3. Repeat bolus once or twice if persistent cardiovascular collapse 2
4. Double infusion rate if blood pressure remains low 2
5. Continue infusion ≥10 minutes after circulatory stability; maximum ~10 mL/kg total 2

Resuscitation modifications:

• Reduce epinephrine doses (standard ACLS doses may worsen toxicity)
• Avoid vasopressin, calcium channel blockers, β-blockers
• Prolonged resuscitation may be required 2

Practical Dosing Algorithm for Ocular Surgery

Step 1: Calculate patient's ideal body weight (height in cm - 100 for men; height in cm - 105 for women) 8

Step 2: Determine maximum safe dose based on agent and epinephrine use

Step 3: Convert to volume based on concentration being used

Step 4: If combining agents (e.g., lidocaine for rapid onset + bupivacaine for prolonged effect), use fractional dose rule:

• (Dose of Agent A / Max Dose of Agent A) + (Dose of Agent B / Max Dose of Agent B) ≤ 1.0 12

Step 5: Document all doses, times, and sites of administration 2, 3

Step 6: Monitor continuously during and for 15 minutes after administration 8

Common Pitfalls to Avoid

• Never dispense topical anesthetics for patient home use (high abuse potential and corneal toxicity) 4
• Do not assume "caine allergy" without formal testing—most reactions are not immunologic 9, 10, 11
• Do not combine IV lidocaine with regional blocks within 4 hours (additive toxicity risk) 8
• Do not use actual body weight for obese patients—use ideal body weight 8
• Do not forget to reduce doses by 30% in infants <6 months 2, 3
• Have 20% lipid emulsion immediately available when using long-acting agents (bupivacaine, ropivacaine) in vascular areas 3

2, 3, 2, 8, 6, 8, 9, 5, 1, 4, 10, 11, 12, 7